TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    5.
    发明公开
    TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS 审中-公开
    TROPOMYOSIN-RELATED KINASE(TRK)抑制剂

    公开(公告)号:EP3080108A1

    公开(公告)日:2016-10-19

    申请号:EP14824251.4

    申请日:2014-12-10

    摘要: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

    摘要翻译: 原肌球蛋白相关激酶抑制剂(Trk抑制剂)是用于治疗疾病的小分子化合物。 Trk抑制剂可以用作药物和药物组合物。 Trk抑制剂可用于治疗炎症性疾病,自身免疫性疾病,骨代谢缺陷和/或癌症,并且特别可用于治疗骨关节炎(OA),疼痛和与OA有关的疼痛。 Trk抑制剂也可用于抑制原肌球蛋白相关激酶A(TrkA),原肌球蛋白相关激酶B(TrkB),原肌球蛋白相关激酶C(TrkC)和/或c-FMS(集落刺激因子-1的细胞受体 (CSF-1))。